Amylyx is proud to announce that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]), for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the U.S.
FDA Approves RELYVRIO™ (previously known as AMX0035) for the treatment of adults with ALS in the U.S.
Health Canada Approves ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) for the Treatment of ALS
Amylyx is proud to announce that Health Canada has approved ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). ALBRIOZA (previously known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death in people living with ALS, either as a stand-alone therapy or when added to existing treatments.
In pursuit of more
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Driven by People
Latest News
Keep in touch
To stay up to date on Amylyx news, click subscribe.